PMID-39343637 – GnRH Antagonists vs Agonists Cardiovascular Safety
Patel S, et al. Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer. Eur Urol Oncol. 2025.
Quick Reference
| Property | Value |
|---|---|
| PMID | 39343637 |
| DOI | — |
| Year | 2025 |
| Journal | European Urology Oncology |
| Study Type | Observational / Cohort |
| Evidence Level | III |
| Sample | Large cohort of prostate cancer patients |
| Peptide(s) Studied | Degarelix, Relugolix, Leuprolide, Goserelin |
Key Findings
- Compared cardiovascular safety of GnRH antagonists (degarelix, relugolix) versus GnRH agonists (leuprolide, goserelin) in real-world prostate cancer patients
- GnRH antagonists demonstrated favorable cardiovascular safety profiles compared to GnRH agonists
- Results support findings from the HERO trial showing reduced major adverse cardiovascular events with antagonists
- Real-world evidence complements randomized trial data
Study Design
Retrospective cohort study comparing cardiovascular outcomes between prostate cancer patients treated with GnRH antagonists versus GnRH agonists. Used administrative health databases for outcome ascertainment.
Limitations
- Retrospective observational design limits causal inference
- Potential for unmeasured confounding
- Selection bias in treatment choice (sicker patients may receive different agents)
- May not capture all cardiovascular events
Clinical Relevance
This real-world evidence study complements the Phase III trial data (HERO, CS21) by examining cardiovascular safety in routine clinical practice. It strengthens the evidence base suggesting GnRH antagonists may offer cardiovascular advantages over agonists, which is particularly relevant for the growing proportion of prostate cancer patients with pre-existing cardiovascular disease.
Related
#research #observational #cohort #peptide #sexual-health #cardiovascular #evidence-level-III